Current controversies in the management of Graves’ hyperthyroidism

References

• Smith TJ, Hegedus L. Graves’ disease. New Eng J Med. 2016 Oct 20;375(16):1552–1565.
   PubMed Web of Science ®Google Scholar
• Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018 May;14(5):301–316. .
   PubMed Web of Science ®Google Scholar
• Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf). 2013 May;78(5):768–776.
   PubMed Web of Science ®Google Scholar
• Brandt F, Green A, Hegedüs L, et al. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011 Oct;165(4):491–497.
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Taylor PN, Evans C, et al. Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019 Apr;7(4):278–287.
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Khan I, Taylor PN. Preconception management of thyroid dysfunction. Clin Endocrinol (Oxf). 2018 Sep;89(3):269–279.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med. 2009 Mar;360(10):994–1001.
   PubMed Web of Science ®Google Scholar
• Wiersinga WM. Quality of life in Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):359–370.
   PubMed Web of Science ®Google Scholar
• Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993 Jun; 22(2):263–277.
   PubMed Web of Science ®Google Scholar
• Burch HB, Cooper DS. Management of Graves disease: a review. Jama. 2015 Dec 15;314(23):2544–2554.
   PubMed Web of Science ®Google Scholar
• Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. BMJ. 2014;349:g5128.
   PubMed Web of Science ®Google Scholar
• Boelaert K, Torlinska B, Holder RL, et al. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab. 2010 Jun;95(6):2715–2726.
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Lazarus JH. Important considerations in the management of Graves’ disease in pregnant women. Expert Rev Clin Immunol. 2015;11(8):947–957.
   PubMed Web of Science ®Google Scholar
• Autilio C, Morelli R, Locantore P, et al. Stimulating TSH receptor autoantibodies immunoassay: analytical evaluation and clinical performance in Graves’ disease. Ann Clin Biochem. 2018 Jan;55(1):172–177.
   PubMed Web of Science ®Google Scholar
• Tozzoli R, Bagnasco M, Giavarina D, et al. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmunity Rev. 2012;Dec;12(2):107–113.
   PubMed Web of Science ®Google Scholar
• McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992 Summer;2(2):155–159.
   PubMed Web of Science ®Google Scholar
• Scappaticcio L, Trimboli P, Keller F, et al. Diagnostic testing for Graves’ or non-Graves’ hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography. Clin Endocrinol (Oxf). 2020 Feb;92(2):169–178.
   PubMed Web of Science ®Google Scholar
• McKee A, Peyerl F. TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis. Am J Manag Care. 2012;18:e1e14. United States.
   Web of Science ®Google Scholar
• Okosieme OE, Chan D, Price SA, et al. The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol (Oxf). 2010 Jan;72(1):122–127.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Bartalena L, Hegedüs L, et al., European thyroid association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–186.
   PubMed Web of Science ®Google Scholar
• Burch HB, Burman KD, Cooper DSA. 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012 Dec;97(12):4549–4558.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Burch HB, Burman KD, et al. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf). 2016 Jan;84(1):115–120.
   PubMed Web of Science ®Google Scholar
• Beshyah SA, Khalil AB, Sherif IH, et al. A survey of clinical practice patterns in management of Graves disease in the Middle East and North Africa. Endocr Pract. 2017 Mar;23(3):299–308.
   PubMed Web of Science ®Google Scholar
• Vaidya B, Williams GR, Abraham P, et al. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf). 2008 May;68(5):814–820.
   PubMed Web of Science ®Google Scholar
• Cox SC, Tamatea JA, Conaglen JV, et al. The management of Graves’ disease in New Zealand 2014. N Z Med J. 2016;129(1436):10–24.
   PubMed Web of Science ®Google Scholar
• Negro R, Attanasio R, Grimaldi F, et al. A 2015 Italian survey of clinical practice patterns in the management of Graves’ disease: comparison with European and North American Surveys. Eur Thyroid J. 2016 Jul;5(2):112–119.
   PubMed Web of Science ®Google Scholar
• Brito JP, Schilz S, Singh Ospina N, et al. Antithyroid drugs-the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016 Aug;26(8):1144–1145.
   PubMed Web of Science ®Google Scholar
• Sjolin G, Holmberg M, Torring O, et al. The long-term outcome of treatment for Graves’ hyperthyroidism. Thyroid. 2019 Nov;29(11):1545–1557.
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Lazarus JH. Current trends in antithyroid drug treatment of Graves’ disease. Expert Opin Pharmacother. 2016 Oct;17(15):2005–2017.
   PubMed Web of Science ®Google Scholar
• Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011 Feb;364(6):542–550.
   PubMed Web of Science ®Google Scholar
• Donovan PJ, McLeod DS, Little R, et al. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’ disease. Eur J Endocrinol. 2016 Dec;175(6):595–603.
   PubMed Web of Science ®Google Scholar
• Törring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. Thyroid study group. J Clin Endocrinol Metab. 1996 Aug;81(8):2986–2993.
   PubMed Web of Science ®Google Scholar
• Abraham-Nordling M, Törring O, Hamberger B, et al. Graves’ disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005 Nov;15(11):1279–1286.
   PubMed Web of Science ®Google Scholar
• Hookham J, Truran P, Allahabadia A, et al. Patients’ perceptions and views of surgery and radioiodine ablation in the definitive management of Graves’ disease. Postgrad Med J. 2017 May;93(1099):266–270.
   PubMed Web of Science ®Google Scholar
• Franklyn JA, Maisonneuve P, Sheppard MC, et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998 Mar;338(11):712–718.
   PubMed Web of Science ®Google Scholar
• Metso S, Jaatinen P, Huhtala H, et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007 Jun;92(6):2190–2196.
   PubMed Web of Science ®Google Scholar
• Boelaert K, Maisonneuve P, Torlinska B, et al. Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab. 2013 May;98(5):1869–1882.
   PubMed Web of Science ®Google Scholar
• Giesecke P, Frykman V, Wallin G, et al. All-cause and cardiovascular mortality risk after surgery versus radioiodine treatment for hyperthyroidism. Br J Surg. 2018 February;105(3):279–286.
   PubMed Web of Science ®Google Scholar
• Essi R, Saara M, Heini H, et al. Cardiovascular morbidity and mortality after treatment of hyperthyroidism with either radioactive iodine or thyroidectomy. Thyroid. 2018 September;28(9):1111–1120.
   PubMed Web of Science ®Google Scholar
• Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, et al. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Thyroid. 2019 March;29(3):332–340.
   PubMed Web of Science ®Google Scholar
• Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, et al. Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab. 2017 July 1;102(7):2301–2309.
   PubMed Web of Science ®Google Scholar
• Kitahara CM, Berrington de Gonzalez A, Bouville A, et al. Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med. 2019 July 1;179(8):1034–1042.
   PubMed Web of Science ®Google Scholar
• Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy follow-up study group. Jama. 1998 July 22-29;280(4):347–355.
   PubMedGoogle Scholar
• Franklyn JA, Maisonneuve P, Sheppard M, et al. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet. 1999 June 19;353(9170):2111–2115.
   PubMed Web of Science ®Google Scholar
• Gronich N, Lavi I, Rennert G, et al. Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid. 2020 Feb;30(2):243–250.
   PubMed Web of Science ®Google Scholar
• Tulchinsky M, Brill AB. Spotlight on the association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism is keeping the highest risk from antithyroid drugs in the blind spot. Clin Nucl Med. 2019 October;44(10):789–791.
   PubMed Web of Science ®Google Scholar
• Grady EE, Zukotynski K, Greenspan BS. Safety of the use of radioactive iodine in patients with hyperthyroidism. JAMA Intern Med. 2019 December 1;179(12):1738–1739.
   PubMedGoogle Scholar
• Taylor PN, Okosieme OE, Chatterjee K, et al. Joint statement from the society for endocrinology and the British thyroid association regarding ‘association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism’. Clin Endocrinol (Oxf). 2020 March;92(3):266–267.
   PubMed Web of Science ®Google Scholar
• NICE. thyroid disease guidelines: national institute of health and care excellence; 2019. [Published 2020 January 27; cited 2019 November 16]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ng10074/documents
   Google Scholar
• Cooper DS. Antithyroid drugs. N Engl J Med. 2005 March;352(9):905–917.
   PubMed Web of Science ®Google Scholar
• Vaidya B, Wright A, Shuttleworth J, et al. Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves’ disease: a retrospective observational study. Clin Endocrinol (Oxf). 2014 October;81(4):610–613.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Molteni M, Leporati P, et al. Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Front Endocrinol (Lausanne). 2017;8:254.
   PubMed Web of Science ®Google Scholar
• Muller I, Moran C, Lecumberri B, et al. 2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. Eur Thyroid J. 2019 July;8(4):173–185.
   PubMed Web of Science ®Google Scholar
• Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 1991 April 4;324(14):947–953.
   PubMed Web of Science ®Google Scholar
• McIver B, Rae P, Beckett G, et al. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996 January 25;334(4):220–224.
   PubMed Web of Science ®Google Scholar
• Abraham P, Avenell A, McGeoch SC, et al. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev (Online). 2010;(1):CD003420.
   PubMed Web of Science ®Google Scholar
• Walsh JP. Management of Graves’ disease in Australia. Aust N Z J Med. 2000 Oct; 30(5):559–566.
   PubMedGoogle Scholar
• Goichot B, Bouee S, Castello-Bridoux C, et al. Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur Thyroid J. 2017 July;6(3):152–159.
   PubMed Web of Science ®Google Scholar
• Ross DS, Burch HB, Cooper DS, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 October;26(10):1343–1421.
   PubMed Web of Science ®Google Scholar
• Konishi T, Okamoto Y, Ueda M, et al. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves’ disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J. 2011;58(2):95–100.
   PubMed Web of Science ®Google Scholar
• Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990 March;70(3):675–679.
   PubMed Web of Science ®Google Scholar
• Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. 2017 October;27(10):1223–1231.
   PubMed Web of Science ®Google Scholar
• Laurberg P, Berman DC, Andersen S, et al. Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid. 2011 September;21(9):951–956.
   PubMed Web of Science ®Google Scholar
• Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J Clin Endocrinol Metab. 1994 January;78(1):98–102.
   PubMed Web of Science ®Google Scholar
• Momotani N, Noh JY, Ishikawa N, et al. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1997 November;82(11):3633–3636.
   PubMed Web of Science ®Google Scholar
• Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009;94(6):1881–1882.
   PubMed Web of Science ®Google Scholar
• Taylor PN, Vaidya B. Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyrotoxicosis in pregnancy. Eur Thyroid J. 2012;1:176–185. Switzerland.
   PubMedGoogle Scholar
• Andersen SL, Olsen J, Wu CS, et al. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013 November;98(11):4373–4381.
   PubMed Web of Science ®Google Scholar
• Clementi M, Di Gianantonio E, Pelo E, et al. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet. 1999;83(1):43–46.
   PubMed Web of Science ®Google Scholar
• Andersen SL, Knosgaard L, Olsen J, et al. Maternal thyroid function, use of antithyroid drugs in early pregnancy, and Birth defects. J Clin Endocrinol Metab. 2019 December 1;104(12):6040–6048.
   PubMed Web of Science ®Google Scholar
• Seo GH, Kim TH, Chung JH. Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. Ann Intern Med. 2018 March 20;168(6):405–413.
   PubMed Web of Science ®Google Scholar
• Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396–2403. United States.
   PubMed Web of Science ®Google Scholar
• Andersen SL, Olsen J, Wu CS, et al. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014 October;24(10):1533–1540.
   PubMed Web of Science ®Google Scholar
• Medicines and healthcare products regulatory agency. Carbimazole: risk of acute pancreatitis; 2019. [cited 2019 December 16]. Available from: https://www.gov.uk/drug-safety-update/carbimazole-risk-of-acute-pancreatitis
   Google Scholar
• Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the american thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017 March;27(3):315–389.
   PubMed Web of Science ®Google Scholar
• Tonacchera M, Chiovato L, Bartalena L, et al. Treatment of Graves’ hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. J Endocrinol Invest. 2020 February;43(2):257–265.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency. Carbimazole: increased risk of congenital malformations; strengthened advice on contraception; 2019 [Published 2020 January 27; cited 2019 December 16]. Available from: https://www.gov.uk/drug-safety-update/carbimazole-increased-risk-of-congenital-malformations-strengthened-advice-on-contraception
   Google Scholar
• Croce L, Di Dalmazi G, Orsolini F, et al. Graves‘ disease and the post-partum period: an intriguing relationship. Front Endocrinol (Lausanne). 2019;10:853.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Capelli V, Coperchini F, et al. Post-partum and non-post-partum relapsing Graves’ hyperthyroidism display different response to anti-thyroid drugs. Eur J Endocrinol. 2018 June;178(6):589–594.
   PubMed Web of Science ®Google Scholar
• Bonnema SJ, Bennedbaek FN, Veje A, et al. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004 Sep;89(9):4439–4444.
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves’ disease. Thyroid. 1995 Aug;5(4):243–247.
   PubMed Web of Science ®Google Scholar
• Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001 August;86(8):3488–3493.
   PubMed Web of Science ®Google Scholar
• Braga M, Walpert N, Burch HB, et al. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid. 2002 February;12(2):135–139.
   PubMed Web of Science ®Google Scholar
• Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007 March 10;334(7592):514.
   PubMedGoogle Scholar
• Bartalena L, Bogazzi F, Pinchera A, et al. Treatment with thionamides before radioiodine therapy for hyperthyroidism: yes or no? J Clin Endocrinol Metab. 2005 February;90(2):1256. author reply 1256-7.
   PubMed Web of Science ®Google Scholar
• Imseis RE, Vanmiddlesworth L, Massie JD, et al. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab. 1998 February;83(2):685–687.
   PubMed Web of Science ®Google Scholar
• Wilson R, McKillop JH, Buchanan LM, et al. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals. Autoimmunity. 1990;8(1):3–7.
   PubMed Web of Science ®Google Scholar
• Sisson JC, Avram AM, Rubello D, et al. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1129–1130.
   PubMed Web of Science ®Google Scholar
• Franklyn JA. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism? Clin Endocrinol (Oxf). 2010 January;72(1):11–12.
   PubMed Web of Science ®Google Scholar
• Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine ((1)(3)(1)I) doses for Graves disease treatment. Clin Nucl Med. 2012 March;37(3):241–244.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Ward L, Salamon EA, et al. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003 March;88(3):978–983.
   PubMed Web of Science ®Google Scholar
• Metso S, Jaatinen P, Huhtala H, et al. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2004 November;61(5):641–648.
   PubMed Web of Science ®Google Scholar
• Canto AU, Dominguez PN, Jimeno CA, et al. Comparison of fixed versus calculated activity of radioiodine for the treatment of Graves disease in adults. Endocrinol Metab (Seoul). 2016 March;31(1):168–173.
   PubMedGoogle Scholar
• Jarlov AE, Hegedus L, Kristensen LO, et al. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf). 1995 September;43(3):325–329.
   PubMed Web of Science ®Google Scholar
• Jaiswal AK, Bal C, Damle NA, et al. Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves’ disease: results of a randomized controlled trial in Indian population. Indian J Endocrinol Metab. 2014 September;18(5):648–654.
   PubMedGoogle Scholar
• de Rooij A, Vandenbroucke JP, Smit JW, et al. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol. 2009 November;161(5):771–777.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228(3):320–330.
   PubMed Web of Science ®Google Scholar
• Escobar-Jiménez F, Férnandez-Soto ML, Luna-López V, et al. Trends in diagnostic and therapeutic criteria in Graves’ disease in the last 10 years. Postgrad Med J. 2000;76(896):340–344.
   PubMed Web of Science ®Google Scholar
• Feroci F, Rettori M, Borrelli A, et al. A systematic review and meta-analysis of total thyroidectomy versus bilateral subtotal thyroidectomy for Graves’ disease. Surgery. 2014;155(3):529–540.
   PubMed Web of Science ®Google Scholar
• Pearce SHS, Dayan C, Wraith DC, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves’ hyperthyroidism: a Phase I study. Thyroid. 2019 July;29(7):1003–1011.
   PubMed Web of Science ®Google Scholar
• Neumann S, Place RF, Krieger CC, et al. Future prospects for the treatment of graves’ hyperthyroidism and eye disease. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2015 September;47(10):789–796.
   Google Scholar
• Gershengorn MC, Neumann S. Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab. 2012 December;97(12):4287–4292.
   PubMed Web of Science ®Google Scholar
• Astwood EB. Landmark article May 8, 1943: treatment of hyperthyroidism with thiourea and thiouracil. By E.B. Astwood. JAMA. 1984 April 6;251(13):1743–1746.
   Google Scholar
• Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997 April;7(2):163–176.
   PubMed Web of Science ®Google Scholar
• Vos XG, Endert E, Zwinderman AH, et al. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2016 April;101(4):1381–1389.
   PubMed Web of Science ®Google Scholar
• Masiello E, Veronesi G, Gallo D, et al. Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest. 2018 December;41(12):1425–1432.
   PubMed Web of Science ®Google Scholar